| http://www.w3.org/ns/prov#value | - Evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients on PREZISTA/ritonavir should prompt consideration of interruption or discontinuation of treatment Severe Skin Reactions: Severe skin reactions (0.4%), accompanied by fever and
|
